On April 4, 2025, Arvinas, Inc. presented promising results from its first-in-human clinical trial of ARV-102, showing over 90% reduction of LRRK2 protein linked to Parkinson's disease, with a favorable safety profile. The trial involved 47 healthy volunteers and indicated that ARV-102 was well tolerated, with common side effects being headache and fatigue.